Medscape

AMD Gene Therapy Sustains Efficacy in First Two-Eye Study

The first study to evaluate both eyes treated with a gene therapy targeting neovascular, or wet, age-related macular degeneration (AMD) has found the treatment as safe and effective in the second eye ...
Healio

Reduced treatment burden, good safety profile seen with bilateral gene therapy for wet AMD

Please provide your email address to receive an email when new articles are posted on . At Clinical Trials at the Summit, Abbey addressed concerns about using gene therapy in both eyes. However, in 11 ...

Opus Genetics reports Phase I/II trial results of OPGx-BEST1 gene therapy

After three months, OPGx-BEST1 was well tolerated with no reports of observed ocular inflammation or adverse events.
The Manila Times

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or ...
FierceBiotech

Atsena eye disease gene therapy hits safety goals, closes retinal splits in phase 1/2

Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease gene therapy. The candidate improved the structure and function of the ...
Healio

VIDEO: Intraoperative OCT increases precision of subretinal gene therapy delivery

Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Lejla Vajzovic, MD, ...
Ophthalmology Times

Rare Disease Day: An abundance of research Is underway to address rare eye diseases

Stargardt programs address ABCA4 payload constraints via dual-AAV platforms (VG801, AAVB-039) and explore first ...

Opus Genetics, Inc.: Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months Early signals of functional and str ...